Treatment
Post-Transplant Cyclophosphamide clinical trials
We’re tracking 41 recruiting studies that include Post-Transplant Cyclophosphamide, each written for real people, not researchers, below.
Recruiting studies
- NCT06041893Recruiting
Stem cell transplant with gentler immune therapy
This trial offers a stem cell transplant from a half-matched (haploidentical) donor for children. It uses an early medicine to calm the immune system and a lower dose of a drug to prevent rejection and graft-versus-host disease.
SeoulAges Any age - NCT04237623RecruitingPhase 2
GM-CSF after transplant using a matched related donor
This Phase 2 study tests whether giving a medicine called GM-CSF after an allogeneic transplant (using a matched related donor) can improve outcomes. Participants must meet health and donor-matching requirements and be eligible to safely receive the treatment and consent to the study.
Atlanta, GeorgiaAges 18–78 - NCT07214688RecruitingPhase 2
Transplant Prep with Chemo, Radiation, and GVHD Prevention for Blood Cancers
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
Washington D.C., District of ColumbiaAges 18–65 - NCT06973668RecruitingPhase 2
Comparing drug combos to prevent graft versus host disease after stem cell transplant
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
Houston, TexasAges 65–75 - NCT03520647RecruitingPhase 2
Haplo transplant for severe bone marrow failure using donor cells
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Bethesda, MarylandAges 4–75 - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT03555851Recruiting
Testing how post-transplant cyclophosphamide affects transplant outcomes
This study looks at whether giving a medicine called cyclophosphamide after a stem cell transplant helps work better and for whom. You may be eligible if you are planning a certain type of transplant and your team plans to give post-transplant cyclophosphamide.
Charlotte, North CarolinaAges 18 years+ - NCT03802773Recruiting
Cord blood transplant with strong chemo to prevent relapse
This trial tests a cord blood transplant using strong (myeloablative) chemotherapy to prepare your body, plus post-transplant treatment to reduce graft-versus-host disease (GVHD). It may help certain blood cancers when other transplant options are limited.
Roma, RMAges 18–75 - NCT03850366RecruitingPhase 2
Haploidentical stem cell transplant with two post-transplant medicines
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
Detroit, MichiganAges 18–65 - NCT04314219RecruitingPhase 3
Preventing GVHD after leukemia stem cell transplant
This Phase 3 study tests whether giving post-transplant cyclophosphamide can better prevent a dangerous immune complication called GVHD compared with the usual standard medicines. You may be eligible if you are in remission from acute leukemia and planning a fully matched related-donor stem cell transplant.
RiyadhAges 14–65 - NCT05126849RecruitingPhase 2
Stem cell transplant using half-matched donor and cyclophosphamide
This trial tests a stem cell transplant option for children or young adults with severe aplastic anemia that did not respond to prior immune-suppressing treatment. It uses a “half-matched” donor and gives post-transplant cyclophosphamide to help the donor cells work and reduce certain immune reactions.
AmiensAges 3–35 - NCT05289167RecruitingPhase 1/Phase 2
Medicines to prevent graft-versus-host disease after a transplant
This trial tests a combination of medicines (post-transplant cyclophosphamide, bortezomib, and abatacept) to lower your chance of developing graft-versus-host disease (when transplanted immune cells attack your body) after a transplant. If you qualify, you’ll receive the study medicines as part of your post-transplant care and be followed closely to check safety and prevention of GvHD.
New Hyde Park, New YorkAges 14–100 - NCT05768035RecruitingPhase 1/Phase 2
Testing SMART101 after half-matched stem cell transplant
This trial studies a new immune treatment called SMART101 given after a half-matched (haploidentical) stem cell transplant that uses post-transplant cyclophosphamide to prevent complications. It mainly checks safety, and may also look at how well SMART101 helps people with blood cancers recover after transplant.
MarseilleAges 18 years+ - NCT05849207RecruitingPhase 1
Cyclophosphamide after transplant for people 65 and older
This early-phase study tests giving cyclophosphamide after a specific type of stem cell transplant (haploidentical) in people age 65 and older. It aims to improve transplant safety and outcomes by adjusting medicine given after the graft is placed.
Los Angeles, CaliforniaAges 65 years+ - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06412497RecruitingPhase 2
Stem cell transplant for aplastic anemia and bone marrow failure
This trial tests a stem cell transplant using a milder conditioning regimen and a drug called post-transplant cyclophosphamide to treat severe aplastic anemia and other acquired bone marrow failure conditions. The goal is to help patients achieve a functioning donor bone marrow with fewer side effects.
Minneapolis, MinnesotaAges birth–75 years - NCT05027945RecruitingPhase 2
Stem cell transplant for people with VEXAS syndrome
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
Bethesda, MarylandAges 18–75 - NCT06681922RecruitingPhase 1/Phase 2
A new combination to prevent graft-versus-host disease after stem cell transplant
This study tests a combination of three drugs—high-dose cyclophosphamide, bortezomib, and abatacept—after a donor stem cell transplant to see if they can better prevent graft-versus-host disease (a condition where donor cells attack the body).
Lake Success, New YorkAges 18 years+ - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06926595RecruitingPhase 2
Stem cell transplant with low-dose chemo for graft-versus-host disease prevention
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
Hershey, PennsylvaniaAges 18 years+ - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Columbus, OhioAges 18 years+ - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75
What Post-Transplant Cyclophosphamide is being studied for
Conditions with recruiting Post-Transplant Cyclophosphamide studies.
Common questions
- Are there clinical trials studying Post-Transplant Cyclophosphamide?
- Yes. Clin2 currently lists 41 recruiting studies that include Post-Transplant Cyclophosphamide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Post-Transplant Cyclophosphamide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Post-Transplant Cyclophosphamide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Post-Transplant Cyclophosphamide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.